Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 21-30 of 46
Solid Tumors
Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery With Solid Tumors and Spinal Metastases
Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery With Solid Tumors and Spinal Metastases More information to come Trial Registration: ClinicalTrials.gov Identifier: NCT02387905 For Researchers ImpactTODAY Newsletters Model of Support Gateway’s Impact Funded Clinical Trials Discovery Grant Apply for a Grant Research FAQ More […]
Amol Ghia, MD
MD Anderson Cancer Center
Blood Cancer
A phase I/II study of ARGX-110 in patients with relapsed/refractory acute myeloid leukemia
A phase I/II study of ARGX-110 in patients with relapsed/refractory acute myeloid leukemia More information to come Trial Registartion: ClinicalTrials.gov Identifier: NCT03030612 For Researchers ImpactTODAY Newsletters Model of Support Gateway’s Impact Funded Clinical Trials Discovery Grant Apply for a Grant Research FAQ More for you Make a Tribute Gift Read Gateway News View Clinical […]
Adrian Ochsenbein, MD
University Hospital, Inselspital
Head/Neck Cancer
Personalized, cell-based antitumor immunization with MVX-ONCO-1, combining subcutaneous implantation of irradiated autologous tumor cells and encapsulated allogeneic cells engineered to release GM-CSF: a single arm Phase II trial
Personalized, cell-based antitumor immunization with MVX-ONCO-1, combining subcutaneous implantation of irradiated autologous tumor cells and encapsulated allogeneic cells engineered to release GM-CSF: a single arm Phase II trial More inforomation to come. Trial Registration: ClinicalTrials.gov Identifier: NCT02999646 For Researchers ImpactTODAY Newsletters Model of Support Gateway’s Impact Funded Clinical Trials Discovery Grant Apply for a Grant […]
Nicolas Mach, MD
Geneva University Hospital
Breast Cancer
Preoperative Breast Radiotherapy: A Tool to Provide Individualized and Biologically-Based Radiation Therapy
Preoperative Breast Radiotherapy: A Tool to Provide Individualized and Biologically-Based Radiation Therapy More information to come. Trial Registration: ClinicalTrials.gov Identifier: NCT02482376 For Researchers ImpactTODAY Newsletters Model of Support Gateway’s Impact Funded Clinical Trials Discovery Grant Apply for a Grant Research FAQ More for you Make a Tribute Gift Read Gateway News View Clinical Trials
Rachel Blitzblau, MD, PhD
Duke University School of Medicine
Kidney Cancer
Combining NeoVax, A Personalized Neoantigen Vaccine, with Ipilimumab to Treat Advanced Clear Cell Renal Carcinoma
Combining NeoVax, A Personalized Neoantigen Vaccine, with Ipilimumab to Treat Advanced Clear Cell Renal Carcinoma More information to come: Trial Registration: ClinicalTrials.gov Identifier: NCT02950766 For Researchers ImpactTODAY Newsletters Model of Support Gateway’s Impact Funded Clinical Trials Discovery Grant Apply for a Grant Research FAQ More for you Make a Tribute Gift Read Gateway News […]
Toni Choueiri,MD
Dana-Farber Cancer Institute
Pediatric Blood Cancer
LLS Pediatric Acute Leukemia (PedAL) Master Clinical Trial
LLS Pediatric Acute Leukemia (PedAL) Master Clinical Trial Summary: Therapeutic options for relapsed AML or some subsets of ALL remain limited. However, recent large-scale discovery efforts using next generation sequencing (NGS) methods have identified recurrent mutations, cellular signaling, and cell surface antigen targets for new therapies. This is a master trial that will screen each […]
Todd Cooper, DO
Leukemia Lymphoma Society / Seattle's Children's
Pediatric Blood Cancer
A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies
A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies Summary: Effective treatment for children and young adults with relapsed/refractory MDS, MDS-associated AML (MDS/AML), treatment related MDS/AML, and relapsed/refractory high-risk ALL/LBL continues to be a major clinical challenge with poor long-term […]
Andrew Place, MD, PhD
Dana-Farber Cancer Institute
Pediatric Blood Cancer
PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy
PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy Summary: Currently, the survival of children diagnosed with AML sits at less than 70%. Despite 80 to 90% of patients achieving first complete remission, 30 to 40% will relapse and outcomes […]
Jennifer Kamens, MD
Stanford University
Pediatric Blood Cancer
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD Summary: Allogeneic hematopoietic stem cell transplants (stem cell transplant from a donor) [HSCT] are an important treatment for high-risk hematologic (blood) malignancies. However, these transplants can result in graft versus host disease (GVHD) which targets the skin, liver, and GI tract. This occurs in about […]
John Levine, MD, MS
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute
Pediatric Blood Cancer
A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia
A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia Summary: Survival rates for children with AML are greater than 60%; however, the outcome for patients with relapsed or refractory disease remains poor with less than 40% becoming long term […]
Jeffrey Rubnitz, MD, PhD
St. Jude Children's Research Hospital
